Company News: GlaxoSmithKline

Share this article:
GlaxoSmithKline dedicated a new $300,000 production facility at its Nashik site in India to the manufacture of albendazole as part of the World Health Organization's anti-lymphatic filariasis program. The plant will produce 300 million treatments of the drug per year. Lymphatic filariasis, or elephantitis, is a tropical parasitic infection spread by mosquitoes and causing grotesque, painful swelling of the limbs, breasts and genitals. An estimated 120 million people in 83 countries are currently infected.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.

Sanofi wants greater MS role

The plan is to bring in-house products to the market as well as through acquisitions.

Mylan buys branded and generic Arixtra

The $225-million deal will give Mylan one of two generics for the deep vein thrombosis drug.